,,iv  #aag? ,,congress  #b;d ,session   
,h4 ,,res4 #idh  ,,9 ,,! ,,h\se ,,(     
,,repres5tatives  ,febru>y #bh1 #bjbb   
,mr4 ,butt]field submitt$ ! foll[+      
resolution2 :i* 0 ref]r$ to ! ,committee
 on ,en]gy & ,comm]ce  ,,resolution     
,recogniz+ ! extraord9>y *all5ges fac$  
by pati5ts ( color ) r>e diseases & !   
ne$ to id5tify & promote evid5c$-bas$   
solutions to alleviate !                
disproportionate burd5 ( r>e diseases on
 ^! communities & support+ ! recognition
 ( ! la/ day 9 ,febru>y z ,r>e ,disease 
,day4  ,:]eas a r>e disease is def9$ z a
 condition affect+ few] ?an #bjj1jjj p 9
 ! ,unit$ ,/ates1 & ov] #g1jjj          
individual diseases are repres5t$ 9 !   
r>e disease community2 ,:]eas           
#be1jjj1jjj to #cj1jjj1jjj individuals 9
 ! ,unit$ ,/ates1 ne>ly #a 9 #aj1 suff] 
f a r>e disease1 & ! majority ( r>e     
diseases />t 9 *ildhood2 ,:]eas r>e     
diseases disproportionately affect p (  
color1 & r>e disord]s su* z s>coidosis1 
sickle cell anemia1 ,kawasaki disease1 &

 "s =ms ( lupus are kn[n to affect      
m9ority populations at high] rates ?an !
 g5]al population2 ,:]eas a long hi/ory 
( discrim9ation & socioeconomic         
inequality has l$ to a heal? crisis = p 
( color 9 ! ,unit$ ,/ates1 & bo? social 
& physical det]m9ants ( heal?1 :i*      
disproportionately negatively affect p (
 color1 contribute to ?is crisis2 ,:]eas
 ! r>e disease community cont9ues to    
face hurdles g5]ally & p ( color face   
additional hurdles 9 _! que/ = c>e1 &   
flaws across ! entire sy/em (t5 h deadly
 consequ5ces & a comp\nd+ effect on !   
c>e t ,black1 ,native ,am]ican1         
,hispanic1 ,asian1 & ,pacific ,isl&]    
individuals ) r>e diseases receive2     
,:]eas ! lack ( in=mation & k ab\t r>e  
diseases by mo/ m$ical pr(essionals c   
result 9 few] diagnoses1 & x takes an   
av]age ( #f ye>s to get a diagnosis ( a 
r>e disease1 & ev5 long] = p ( color2   
,:]eas delays 9 diagnosis & treatm5t c  
result 9 s]i\s disease progression1 & _m
 pati5ts are misdiagnos$ multiple times 

be=e receiv+ an accurate diagnosis2     
,:]eas ov] #ie p]c5t ( r>e diseases lack
 ,food & ,drug ,adm9i/ration-approv$    
treatm5ts1 & p ( color h less access to 
speciali/s & innovative !rapies2 ,:]eas 
p ( color make up m ?an #ch p]c5t ( !   
,unit$ ,/ates population1 b p ( color   
comprise only #af p]c5t ( cl9ical rese>*
 /udy p>ticipants2 ,:]eas r>e disease   
speciali/s are limit$ 9 numb] & are     
geographically scatt]$1 comp\nd+ !      
*all5ge ( secur+ a timely diagnosis &   
treatm5t f kn[l$geable pr(essionals1 &  
access to ^! speciali/s1 advanc$        
diagno/ic te/s1 & to ! limit$ !rapies   
available c be prohibitively exp5sive = 
_m families & geographically out ( rea*2
 ,:]eas innovative heal? managem5t      
/rategies & pati5t-c5t]$ c>e c improve  
access to c>e & treatm5t = all          
individuals liv+ ) r>e disease1 includ+ 
p ( color2 ,:]eas improv+ ! /ate (      
rese>* & cl9ical trials to address      
pipel9e & sy/emic issues t inhibit      
communities ( color f p>ticipat+ 9      

rese>* & cl9ical trials1 increas+ !     
numb] ( r>e disease rese>*]s & m$ical   
/ud5ts t come f communities ( color1 &  
increas+ ! p>ticipation ( communities ( 
color 9 rese>* & cl9ical trials is      
necess>y to improve c>e = pati5ts (     
color ) r>e diseases2 ,:]eas #hj p]c5t (
 r>e diseases are g5etic1 & "s g5etic   
disord]s su* z sickle cell anemia1      
?alassemia1 & h,a,t,t,r amyloidosis are 
m likely to occur among p :o trace _!   
ance/ry to a p>ticul> geographic area2  
,:]eas #hj p]c5t ( ! p>ticipants 9      
g5ome-wide association /udies are (     
,european desc5t1 :i* has deva/at+      
implications = div]se populations ) r>e 
disease2 ,:]eas prop] und]/&+ ( !       
g5omics ( div]se e?nic populations is   
critical to increas+ ! spe$ ( diagnosis 
= r>e diseases2 ,:]eas1 relative to !   
numb] ( diseases & scope ( ne$1 v few   
!rapies = r>e diseases1 kn[n z orphan   
drugs1 are be+ develop$ due1 9 "p1 to ! 
limit$ preval5ce ( populations ) r>e    
disease2 ,:]eas ! g5esis ( _m inequities

 9 ! ,unit$ ,/ates heal? c>e sy/em /em f
 a precursor disp>ity 9 rese>* &        
availability ( new treatm5ts2 ,:]eas    
pati5ts & c>egiv]s ( color are          
und]repres5t$ 9 ! r>e disease advocacy  
gr\ps t h be5 s important 9 educat+ &   
provid+ res\rces to ^? newly diagnos$ ) 
a r>e disease2 ,:]eas gr\ps l ! ,r>e    
,disease ,div]sity ,coalition1 compris$ 
( r>e disease exp]ts1 heal? & div]sity  
advocates1 & indu/ry lead]s1 are d$icat$
 to develop+ & implem5t+ /rategies to   
r$uce inequalities & are work+ to       
improve ! quality & accessibility ( c>e 
by id5tify+ ! mo/ press+ problems1 & mo/
 promis+ solutions1 9 areas t include-- 
7#a7 delays 9 ! diagnosis & treatm5t (  
r>e diseases2  7#b7 rese>* & cl9ical    
/udies2  7#c7 education & engagem5t (   
provid]s1 pati5ts1 & nurs+ /aff2 &  7#d7
 public policy2 & ,:]eas cont9u$        
education ( policymak]s on ! importance 
( address+ racial disp>ities is ne$$3   
,n[1 !re=e1 be x  ,t ! ,h\se (          
,repres5tatives-- 7#a7 recognizes !     

importance ( decreas+ r>e diseases among
 all populations1 especially among p (  
color2  7#b7 recognizes ! unique factors
 t impact p ( color1 includ+ racism &   
hi/oric bias & its l+]+ disp>ate social1
 economic1 & heal? effects on ^!        
communities2  7#c7 recognizes !         
necessity ( spread+ aw>5ess & improv+   
pati5t & provid] education & engagem5t z
 a means to r$uce delays 9 r>e disease  
diagnosis & improv+ r>e disease         
treatm5t2  7#d7 supports cont9u$ rese>* 
& developm5t ( drugs = r>e diseases to  
address unmet m$ical ne$s ( pati5ts )   
r>e diseases2 &  7#e7 supports !        
designation ( ,r>e ,disease ,day4